SDI Review Form 1.6

Journal Name:	**Ophthalmology Research: An international Journal**
Manuscript Number:	**2014_OR_10573**
Title of the Manuscript:	**ROCK INHIBITORS: FUTURE OF ANTI-GLAUCOMA MEDICATION???**
Type of the Article	**Minireview Article**

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.
To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline)

SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	**Author's comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Compulsory REVISION comments		
Minor REVISION comments	Betaxololl, Tafluprost and other medications should be added in page 2 lines 33-35 Line 92 after et al put a ","	
Optional/General comments	The authors should add the theoretical effect on human IOP, in other word which should be the IOP reduction? Are the drug company happy of this result or they looking for a better association?	

Reviewer Details:

Name:	**Iester Michele**
Department, University & Country	**DiNOGMI, University of Genoa, Italy**